Researchers analyzed data from the FAERS to determine the prevalence of interstitial lung disease among patients with cancer receiving antibody-drug conjugates ...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) ...
Better diagnostics and more treatment options have modestly improved interstitial lung disease management in patients with ...
4don MSN
Safeguard your family against pneumococcal disease: Why vaccination matters now more than ever
Pneumococcal infections pose a significant public health threat, particularly for adults and those with underlying health ...
ERS/EULAR guidelines outline best practices for diagnosis, monitoring, and treatment of connective tissue disease-related ILD ...
Allrock Bio Inc. secured $50 million in a series A round co-led by Versant Ventures and Westlake Biopartners to advance ROC-101, an oral pan-rho-associated protein kinase (ROCK) inhibitor to treat ...
Activity in some clinical parameters is leading Atyr Pharma Inc. to plan a sit-down with regulators, even though the tRNA synthetase-derived drug efzofitimod missed its primary endpoint of steroid ...
The company’s market value was largely wiped out after a therapy it’s been developing for pulmonary sarcoidosis missed its ...
Tyr Pharma ( NASDAQ: ATYR) stock fell after its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a ...
ATyr on Monday said the Phase 3 study of efzofitimod in the interstitial lung disease pulmonary sarcoidosis missed its primary endpoint of change from baseline in daily steroid doses at 48 weeks.
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback